Catalyst Pharmaceutical Partners Announces Completion of Enrollment in CPP-109 Phase II(b) Clinical Trial for the Treatment of Cocaine Addiction

Catalyst Pharmaceutical Partners, Inc.

today announced that patient enrollment in its CPP-109 vigabatrin Phase II(b) clinical trial has reached its goal of 200 cocaine dependent subjects. The Company anticipates that screening of all remaining subjects will be completed this week and the total number enrolled will be approximately 210. Top-line results of the clinical trial are expected to be available early in the first quarter of 2013. "We are pleased to have accomplished this important milestone in the development of CPP-109 by completing enrollment in the CPP-109 Phase II(b) clinical trial within the expected timeframe," said Patrick J. McEnany, Chief Executive Officer of Catalyst. "There is a major need for effective and well-tolerated treatments for patients with cocaine addiction, and CPP-109 potentially represents a breakthrough product for them. I would like to thank our partners at the National Institute on Drug Abuse and the Veterans Administration, the clinical investigators and study site personnel for their dedication, as well as the subjects and their families who are participating in the trial."